<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46704">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498236</url>
  </required_header>
  <id_info>
    <org_study_id>R21</org_study_id>
    <nct_id>NCT02498236</nct_id>
  </id_info>
  <brief_title>Target Engagement for Oxytocin: Dose Ranging Study</brief_title>
  <acronym>R21Dose</acronym>
  <official_title>Target Engagement for Oxytocin: Response to 8 Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two
      proposed measures of target engagement in brain. The targets are (1) the suppression of a
      particular wave form (mu) on the electroencephalogram (EEG) while subjects observe a
      socially relevant form of motion and (2) pupil dilation will subjects identify faces showing
      different emotions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with schizophrenia spectrum disorders will be randomly assigned to one of 8 doses
      of oxytocin. After screening and informed consent subjects will receive either their
      assigned dose or a placebo. Thirty minutes following the drug administration patients will
      be evaluated on the EEG and pupillometry tasks followed by two tests that evaluate social
      salience. One week later subjects will have a second challenge in the alternative (drug or
      placebo) condition.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mu suppression on EEG</measure>
    <time_frame>30-90 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupil Dilation while observing faces</measure>
    <time_frame>30-90 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Schizophrenia Spectrum</condition>
  <arm_group>
    <arm_group_label>Oxytocin 6-84 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be administered intranasal placebo using the same spray volume as experimental condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Oxytocin</intervention_name>
    <arm_group_label>Oxytocin 6-84 IU</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia, Schizoaffective Disorder, Delusional Disorder

          -  Able to cooperate with study procedures

        Exclusion Criteria:

          -  Serious medical condition or substance use

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephen R Marder, MD</last_name>
    <phone>310-268-3647</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Himali Karunaratne, MBBS</last_name>
    <phone>310-478-3711</phone>
    <phone_ext>44932</phone_ext>
  </overall_contact_backup>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 14, 2015</lastchanged_date>
  <firstreceived_date>July 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Stephen R. Marder</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Psychosis</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
